Report Information More information from: https ://www.wis eguyreports .com/reports /495875
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H1 2016 Report / Search Code: WGR495875
Price
1-user P DF : $ 2000.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 4000.0
Enterprise P DF : $ 6000.0
Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H1 2016’, provides an overview of the MethicillinSus ceptible Staphylococcus aureus (MSSA) Infections pipeline lands cape. The report provides comprehens ive information on the therapeutics under development for Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections , complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in therapeutic development for Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape of MethicillinSus ceptible Staphylococcus aureus (MSSA) Infections - The report reviews pipeline therapeutics for Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections therapeutics and enlis ts all their major and minor projects - The report as s es s es Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news related to pipeline therapeutics for MethicillinSus ceptible Staphylococcus aureus (MSSA) Infections Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under
development for Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding MethicillinSus ceptible Staphylococcus aureus (MSSA) Infections pipeline depth and focus of Indication therapeutics - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope - Modify the therapeutic portfolio by identifying dis continued projects and unders tanding the factors that drove them from pipeline Contents:
Table of Contents Table of Contents 2 Lis t of Tables 4 Lis t of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections Overview 6 Therapeutics Development 7 Pipeline Products for Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Overview 7 Pipeline Products for Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Comparative Analys is 8 Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Therapeutics under Development by Companies 9 Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Therapeutics under Inves tigation by Univers ities /Ins titutes 10 Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Products under Development by Companies 13 Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Products under Inves tigation by Univers ities /Ins titutes 14 Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Companies Involved in Therapeutics Development 15 Ars anis Bios ciences GmbH 15 ContraFect Corporation 16 Debiopharm International SA 17 Sealife PHARMA GMBH 18 Sumitomo Dainippon Pharma Co., Ltd. 19 Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Therapeutics As s es s ment 20 As s es s ment by Monotherapy Products 20 As s es s ment by Target 21 As s es s ment by Mechanis m of Action 23 As s es s ment by Route of Adminis tration 25 As s es s ment by Molecule Type 27 Drug Profiles 29 ASN-100 - Drug Profile 29 Product Des cription 29 Mechanis m of Action 29 R& D Progres s 29 CF-301 - Drug Profile 31 Product Des cription 31 Mechanis m of Action 31 R& D Progres s 31 Debio-1450 - Drug Profile 32 Product Des cription 32 Mechanis m of Action 32 R& D Progres s 32 SLP-0904 - Drug Profile 33 Product Des cription 33 Mechanis m of Action 33 R& D Progres s 33 SLP-0905 - Drug Profile 34 Product Des cription 34 Mechanis m of Action 34 R& D Progres s 34 SM-295291 - Drug Profile 35 Product Des cription 35 Mechanis m of Action 35
R& D Progres s 35 SM-369926 - Drug Profile 36 Product Des cription 36 Mechanis m of Action 36 R& D Progres s 36 Small Molecules for Bacterial Infections - Drug Profile 37 Product Des cription 37 Mechanis m of Action 37 R& D Progres s 37 Synthetic Peptide for Oncology and Infectious Dis eas e - Drug Profile 38 Product Des cription 38 Mechanis m of Action 38 R& D Progres s 38 targocil - Drug Profile 39 Product Des cription 39 Mechanis m of Action 39 R& D Progres s 39 Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Recent Pipeline Updates 40 Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects 44 Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Dis continued Products 45 Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Product Development Miles tones 46 Featured News & Pres s Releas es 46 Dec 02, 2014: ContraFect Submits Complete Res pons e to IND Clinical Hold for CF301 46 Appendix 47 Methodology 47 Coverage 47 Secondary Res earch 47 Primary Res earch 47 Expert Panel Validation 47 Contact Us 47 Dis claimer 48 Lis t of Tables Number of Products under Development for Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections , H1 2016 7 Number of Products under Development for Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Comparative Analys is , H1 2016 8 Number of Products under Development by Companies , H1 2016 9 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 10 Comparative Analys is by Clinical Stage Development, H1 2016 11 Comparative Analys is by Early Stage Development, H1 2016 12 Products under Development by Companies , H1 2016 13 Products under Inves tigation by Univers ities /Ins titutes , H1 2016 14 Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Ars anis Bios ciences GmbH, H1 2016 15 Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Pipeline by ContraFect Corporation, H1 2016 16 Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Debiopharm International SA , H1 2016 17 Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sealife PHARMA GMBH, H1 2016 18 Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 19 As s es s ment by Monotherapy Products , H1 2016 20 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanis m of Action, H1 2016 24 Number of Products by Stage and Route of Adminis tration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 28 Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections Therapeutics Recent Pipeline Updates , H1 2016 40 Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects , H1 2016 44 Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Dis continued Products , H1 2016 45 Lis t of Figures Number of Products under Development for Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections , H1 2016 7 Number of Products under Development for Methicillin-Sus ceptible Staphylococcus aureus (MSSA) Infections - Comparative Analys is , H1 2016 8 Number of Products under Development by Companies , H1 2016 9 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 10 Comparative Analys is by Clinical Stage Development, H1 2016 11 Comparative Analys is by Early Stage Products , H1 2016 12 As s es s ment by Monotherapy Products , H1 2016 20
Number Number Number Number Number Number Number Number
of of of of of of of of
Products Products Products Products Products Products Products Products
by by by by by by by by
Top 10 Targets , H1 2016 21 Stage and Targets , H1 2016 21 Mechanis m of Actions , H1 2016 23 Stage and Mechanis m of Actions , H1 2016 23 Routes of Adminis tration, H1 2016 25 Stage and Routes of Adminis tration, H1 2016 25 Molecule Types , H1 2016 27 Stage and Molecule Types , H1 2016 27
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349